Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2021

01-12-2021 | Solid Tumor | Review

Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

Authors: Hamid Khodayari, Saeed Khodayari, Elmira Ebrahimi, Farimah Hadjilooei, Miko Vesovic, Habibollah Mahmoodzadeh, Tomo Saric, Wilfried Stücker, Stefaan Van Gool, Jürgen Hescheler, Karim Nayernia

Published in: Cancer Immunology, Immunotherapy | Issue 12/2021

Login to get access

Abstract

Nowadays, natural killer (NK) cell-based immunotherapy provides a practical therapeutic strategy for patients with advanced solid tumors (STs). This approach is adaptively conducted by the autologous and identical NK cells after in vitro expansion and overnight activation. However, the NK cell-based cancer immunotherapy has been faced with some fundamental and technical limitations. Moreover, the desirable outcomes of the NK cell therapy may not be achieved due to the complex tumor microenvironment by inhibition of intra-tumoral polarization and cytotoxicity of implanted NK cells. Currently, stem cells (SCs) technology provides a powerful opportunity to generate more effective and universal sources of the NK cells. Till now, several strategies have been developed to differentiate types of the pluripotent and adult SCs into the mature NK cells, with both feeder layer-dependent and/or feeder laye-free strategies. Higher cytokine production and intra-tumoral polarization capabilities as well as stronger anti-tumor properties are the main features of these SCs-derived NK cells. The present review article focuses on the principal barriers through the conventional NK cell immunotherapies for patients with advanced STs. It also provides a comprehensive resource of protocols regarding the generation of SCs-derived NK cells in an ex vivo condition.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
2.
Shaked Y (2019) The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer 19:667–685PubMed
3.
Gavhane Y, Shete A, Bhagat A, Shinde V, Bhong K, Khairnar G, Yadav A (2011) Solid tumors: facts, challenges and solutions. Int J Pharm Sci Res 2:1–12
4.
Luke JJ, Lemons JM, Karrison TG et al (2018) Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol 36:1611PubMedPubMedCentral
5.
Veluchamy JP, Lopez-Lastra S, Spanholtz J et al (2017) In vivo efficacy of umbilical cord blood stem cell-derived NK cells in the treatment of metastatic colorectal cancer. Front Immunol 8:87PubMedPubMedCentral
6.
Restifo NP, Smyth MJ, Snyder A (2016) Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 16:121PubMedPubMedCentral
7.
Mohsenikia M, Farhangi B, Alizadeh AM et al (2016) Therapeutic effects of dendrosomal solanine on a metastatic breast tumor. Life Sci 148:260–267PubMed
8.
Dupuis F, Lamant L, Gerard E et al (2018) Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. Br J Cancer 119:193–199PubMedPubMedCentral
9.
Somasundaram R, Zhang G, Fukunaga-Kalabis M et al (2017) Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 8:1–16
10.
Shiri S, Alizadeh AM, Baradaran B, Farhanghi B, Shanehbandi D, Khodayari S, Khodayari H, Tavassoli A (2015) Dendrosomal curcumin suppresses metastatic breast cancer in mice by changing m1/m2 macrophage balance in the tumor microenvironment. Asian Pac J Cancer Prev 16:3917–3922PubMed
11.
Farhanji B, Latifpour M, Alizadeh AM, Khodayari H, Khodayari S, Khaniki M, Ghasempour S (2015) Tumor suppression effects of myoepithelial cells on mice breast cancer. Eur J Pharmacol 765:171–178PubMed
12.
Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 10:3699–3707PubMed
13.
Hermanson DL, Bendzick L, Pribyl L, McCullar V, Vogel RI, Miller JS, Geller MA, Kaufman DS (2016) Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer. St Cells 34:93–101
14.
Koepsell SA, Miller JS, McKenna DH Jr (2013) Natural killer cells: a review of manufacturing and clinical utility. Transfusion 53:404–410PubMed
15.
Hoogstad-van Evert JS, Cany J, van den Brand D et al (2017) Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice. Oncoimmunology 6:e1320630PubMedPubMedCentral
16.
Zeng J, Tang SY, Toh LL, Wang S (2017) Generation of “off-the-shelf” natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. St Cell Rep 9:1796–1812
17.
18.
O’Brien KL, Finlay DK (2019) Immunometabolism and natural killer cell responses. Nat Rev Immunol 19:282–290PubMed
19.
He Y, Tian Z (2017) NK cell education via nonclassical MHC and non-MHC ligands. Cell Mol Immunol 14:321–330PubMed
20.
Lysakova-Devine T, O’Farrelly C (2014) Tissue-specific NK cell populations and their origin. J Leukoc Biol 96:981–990PubMed
21.
Zhang Y, Wallace DL, De Lara CM et al (2007) In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121:258–265PubMedPubMedCentral
22.
Walzer T, Bléry M, Chaix J et al (2007) Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci 104:3384–3389PubMedPubMedCentral
23.
Wang X, Sun R, Hao X, Lian Z-X, Wei H, Tian Z (2019) IL-17 constrains natural killer cell activity by restraining IL-15–driven cell maturation via SOCS3. Proc Natl Acad Sci 116:17409–17418PubMedPubMedCentral
24.
Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE (2010) Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol 11:585PubMed
25.
26.
27.
Male V, Nisoli I, Kostrzewski T, Allan DS, Carlyle JR, Lord GM, Wack A, Brady HJ (2014) The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression. J Exp Med 211:635–642PubMedPubMedCentral
28.
de Jonge K, Ebering A, Nassiri S, Maby-El Hajjami H, Ouertatani-Sakouhi H, Baumgaertner P, Speiser DE (2019) Circulating CD56 bright NK cells inversely correlate with survival of melanoma patients. Sci Rep 9:1–10
29.
Crome SQ, Lang PA, Lang KS, Ohashi PS (2013) Natural killer cells regulate diverse T cell responses. Trends Immunol 34:342–349PubMed
30.
Ferlazzo G, Thomas D, Lin S-L, Goodman K, Morandi B, Muller WA, Moretta A, Münz C (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172:1455–1462PubMed
31.
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 97:3146–3151PubMed
32.
Vosshenrich CA, García-Ojeda ME, Samson-Villéger SI et al (2006) A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 7:1217–1224PubMed
33.
Grégoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, Walzer T (2007) The trafficking of natural killer cells. Immunol Rev 220:169–182PubMedPubMedCentral
34.
Wendel M, Galani IE, Suri-Payer E, Cerwenka A (2008) Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands. Can Res 68:8437–8445
35.
Hydes T, Noll A, Salinas-Riester G et al (2018) IL-12 and IL-15 induce the expression of CXCR6 and CD49a on peripheral natural killer cells. Immun Inflamm Dis 6:34–46PubMed
36.
Ishida Y, Migita K, Izumi Y et al (2004) The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. FEBS Lett 569:156–160PubMed
37.
Li C, Ge B, Nicotra M, Stern JN, Kopcow HD, Chen X, Strominger JL (2008) JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proc Natl Acad Sci 105:3017–3022PubMedPubMedCentral
38.
Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN (1999) Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity 11:225–230PubMed
39.
Samson SI, Richard O, Tavian M et al (2003) GATA-3 promotes maturation, IFN-γ production, and liver-specific homing of NK cells. Immunity 19:701–711PubMed
40.
Kallies A, Carotta S, Huntington ND, Bernard NJ, Tarlinton DM, Smyth MJ, Nutt SL (2011) A role for Blimp1 in the transcriptional network controlling natural killer cell maturation. Blood 117:1869–1879PubMed
41.
Ohno S-i, Sato T, Kohu K, Takeda K, Okumura K, Satake M, Habu S (2008) Runx proteins are involved in regulation of CD122, Ly49 family and IFN-γ expression during NK cell differentiation. Int Immunol 20:71–79PubMed
42.
Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, Wu L, Butcher EC (2001) Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166:6477–6482PubMed
43.
Inngjerdingen M, Damaj B, Maghazachi AA (2001) Expression and regulation of chemokine receptors in human natural killer cells. Blood 97:367–375PubMed
44.
Edsparr K, Speetjens FM, Mulder-Stapel A, Goldfarb RH, Basse PH, Lennernäs B, Kuppen PJ, Albertsson P (2010) Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YT. J Immunother 33:475 (Hagerstown, Md.: 1997)PubMedPubMedCentral
45.
Taub DD, Sayers TJ, Carter C, Ortaldo JR (1995) Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 155:3877–3888PubMed
46.
Albertsson P, Kim M, Jonges L, Kitson R, Kuppen P, Johansson B, Nannmark U, Goldfarb R (2000) Matrix metalloproteinases of human NK cells. Vivo (Athens, Greece) 14:269–276
47.
Goda S, Inoue H, Umehara H et al (2006) Matrix metalloproteinase-1 produced by human CXCL12-stimulated natural killer cells. Am J Pathol 169:445–458PubMedPubMedCentral
48.
Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, Rees RC (1997) Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 158:2327–2333PubMed
49.
Quatrini L, Molfetta R, Zitti B et al (2015) Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells. Sci Signal 8:ra108–ra108PubMed
50.
Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L (2019) Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol 16:430–441PubMedPubMedCentral
51.
Luu TT, Nguyen N-A, Ganesan S, Meinke S, Kadri N, Alici E, Höglund P (2019) A brief IL-15 pulse results in JAK3-dependent phosphorylation of ITAM-associated signaling molecules and a long-lasting priming imprint in mouse NK cells. SSRN Electron J. https://​doi.​org/​10.​2139/​ssrn.​3351831 (Available at SSRN 3351831)CrossRef
52.
Raneros AB, Puras AM, Rodriguez RM et al (2017) Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. Oncotarget 8:31959PubMedPubMedCentral
53.
López-Cobo S, Romera-Cárdenas G, García-Cuesta EM, Reyburn HT, Valés-Gómez M (2015) Transfer of the human NKG 2D ligands UL 16 binding proteins (ULBP) 1–3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP-recipient natural killer cells. Immunology 146:70–80PubMedPubMedCentral
54.
Yang L, Shen M, Xu LJ, Yang X, Tsai Y, Keng PC, Chen Y, Lee SO (2017) Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. Sci Rep 7:1–13
55.
Vivier E, Nunès JA, Vély F (2004) Natural killer cell signaling pathways. Science 306:1517–1519PubMed
56.
Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K (2001) Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) contributes to interferon γ–dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661–670PubMedPubMedCentral
57.
Wigginton JM, Gruys E, Geiselhart L et al (2001) IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Investig 108:51–62PubMedPubMedCentral
58.
Saric T, Chang S-C, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL (2002) An IFN-γ–induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I–presented peptides. Nat Immunol 3:1169–1176PubMed
59.
Koya T, Yanagisawa R, Higuchi Y, Sano K, Shimodaira S (2017) Interferon-α-inducible dendritic cells matured with OK-432 exhibit TRAIL and fas ligand pathway-mediated killer activity. Sci Rep 7:1–11
60.
Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(23):5591–5596 (The Company of Biologists Ltd)PubMed
61.
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322PubMed
62.
Garris CS, Luke JJ (2020) Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response. Clin Cancer Res 26:3901–3907PubMedPubMedCentral
63.
Straussman R, Morikawa T, Shee K et al (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500–504PubMedPubMedCentral
64.
Khodayari H, Chamani R, Khodayari S, Alizadeh AM (2016) A glance into cancer stem cells. J Kerman Univ Med Sci 23:515–542
65.
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59PubMed
66.
Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H (2006) CD4 (+) CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55:1064–1071PubMed
67.
Porembka MR, Mitchem JB, Belt BA, Hsieh C-S, Lee H-M, Herndon J, Gillanders WE, Linehan DC, Goedegebuure P (2012) Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 61:1373–1385PubMedPubMedCentral
68.
Murray S, Lundqvist A (2016) Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: on being in the right place at the right time, with resilience. Hum Vaccin Immunother 12:607–611PubMed
69.
Ren J, Zeng W, Tian F, Zhang S, Wu F, Qin X, Zhang Y, Lin Y (2019) Myeloid-derived suppressor cells depletion may cause pregnancy loss via upregulating the cytotoxicity of decidual natural killer cells. Am J Reprod Immunol 81:e13099PubMed
70.
Hoechst B, Voigtlaender T, Ormandy L et al (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50:799–807PubMed
71.
Li H, Han Y, Guo Q, Zhang M, Cao X (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol 182:240–249PubMed
72.
Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y (2006) CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176:1582–1587PubMed
73.
Littwitz-Salomon E, Malyshkina A, Schimmer S, Dittmer U (2018) The cytotoxic activity of natural killer cells is suppressed by IL-10+ regulatory T cells during acute retroviral infection. Front Immunol 9:1947PubMedPubMedCentral
74.
Costantini C, Cassatella MA (2011) The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity. J Leukoc Biol 89:221–233PubMed
75.
Li T, Yang Y, Hua X, Wang G, Liu W, Jia C, Tai Y, Zhang Q, Chen G (2012) Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett 318:154–161PubMed
76.
Li T, Yi S, Liu W, Jia C, Wang G, Hua X, Tai Y, Zhang Q, Chen G (2013) Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity. Med Oncol 30:663PubMed
77.
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L (2008) Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood J Am Soc Hematol 111:1327–1333
78.
Oyer JL, Gitto SB, Altomare DA, Copik AJ (2018) PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology 7:e1509819PubMedPubMedCentral
79.
Juliá EP, Amante A, Pampena MB, Mordoh J, Levy EM (2018) Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells. Front Immunol 9:2140PubMedPubMedCentral
80.
Sarvaria A, Jawdat D, Madrigal JA, Saudemont A (2017) Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front Immunol 8:329PubMedPubMedCentral
81.
Liang S, Niu L, Xu K, Wang X, Liang Y, Zhang M, Chen J, Lin M (2017) Tumor cryoablation in combination with natural killer cells therapy and herceptin in patients with HER2-overexpressing recurrent breast cancer. Mol Immunol 92:45–53PubMed
82.
Lin M, Liang S, Wang X, Liang Y, Zhang M, Chen J, Niu L, Xu K (2017) Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. J Cancer Res Clin Oncol 143:2607–2618PubMed
83.
Sakamoto N, Ishikawa T, Kokura S et al (2015) Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med 13:1–13
84.
Li R, Wang C, Liu L et al (2012) Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 61:2125–2133PubMed
85.
Pérez-Martínez A, Fernández L, Valentín J et al (2015) A phase I/II trial of interleukin-15–stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy 17:1594–1603PubMed
86.
Ardolino M, Raulet DH (2016) Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors. Oncoimmunology 5:e1002725PubMed
87.
Fiedler W, Zeller W, Peimann C-J, Weh H-J, Hossfeld D (1991) A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer. Klin Wochenschr 69:261–268PubMed
88.
Hayakawa M, Hatano T, Ogawa Y, Gakiya M, Ogura H, Osawa A (1994) Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rlL-2. Urol Int 53:117–124PubMed
89.
Ueda Y, Yamagishi H, Tanioka Y, Fujiwara H, Fuji N, Itoh T, Fujiki H, Yoshimura T, Oka T (1999) Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology 46:1274–1279PubMed
90.
Law TM, Motzer RJ, Mazumdar M et al (1995) Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824–832PubMed
91.
Hashimoto W, Tanaka F, Robbins PD, Taniguchi M, Okamura H, Lotze MT, Tahara H (2003) Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18. Int J Cancer 103:508–513PubMed
92.
Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677–4685PubMed
93.
Multhoff G, Seier S, Stangl S et al (2020) Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized phase II clinical trial. Clin Cancer Res 26:5368–5379PubMed
94.
Knorr DA et al (2014) Clinical utility of natural killer cells in cancer therapy and transplantation. Seminars in immunology. Vol 26, No 2. Academic Press
95.
Liang S, Lin M, Niu L, Xu K, Wang X, Liang Y, Zhang M, Du D, Chen J (2018) Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC). Am J Cancer Res 8:879PubMedPubMedCentral
96.
Ishikawa T, Okayama T, Sakamoto N et al (2018) Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer. Int J Cancer 142:2599–2609PubMed
97.
Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2008) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10:625–632PubMed
98.
Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T (2016) NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother 65:485–492PubMed
99.
Gong J-H, Maki G, Klingemann HG (1994) Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652–658PubMed
100.
Božič J, Stoka V, Dolenc I (2018) Glucosamine prevents polarization of cytotoxic granules in NK-92 cells by disturbing FOXO1/ERK/paxillin phosphorylation. PLoS ONE 13:e0200757PubMedPubMedCentral
101.
Montagner IM, Penna A, Fracasso G, Carpanese D, Pietà AD, Barbieri V, Zuccolotto G, Rosato A (2020) Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer. Cells 9:1382PubMedCentral
102.
Wu A, Wiesner S, Xiao J, Ericson K, Chen W, Hall WA, Low WC, Ohlfest JR (2007) Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J Neurooncol 83:121–131PubMed
103.
Bolourian A, Mojtahedi Z (2017) Possible damage to immune-privileged sites in natural killer cell therapy in cancer patients: side effects of natural killer cell therapy. Immunotherapy 9:281–288PubMed
104.
Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T (2004) Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24:1861–1871PubMed
105.
Mantia CM, Buchbinder EI (2019) Immunotherapy toxicity. hematology/oncology. Clinics 33:275–290
106.
Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142PubMed
107.
Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, Han W (2017) Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Prot Cell 8:861–877
108.
Barkholt L, Alici E, Conrad R et al (2009) Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 1:753–764PubMed
109.
Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA (2010) A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 59:1781–1789PubMed
110.
Yang YJ, Park JC, Kim HK, Kang JH, Park SY (2013) A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second-or third-line treatment: phase IIa study. Anticancer Res 33:2115–2122PubMed
111.
Motohashi S, Ishikawa A, Ishikawa E et al (2006) A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non–small cell lung cancer. Clin Cancer Res 12:6079–6086PubMed
112.
Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17:6287–6297PubMedPubMedCentral
113.
Lin M, Xu K, Liang S, Wang X, Liang Y, Zhang M, Chen J, Niu L (2017) Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer. Immunol Lett 184:98–104PubMed
114.
Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, DePriest MC (2009) Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 32:914–919PubMed
115.
Tonn T, Schwabe D, Klingemann HG et al (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15:1563–1570PubMed
116.
Geller MA, Cooley S, Judson PL et al (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98–107PubMed
117.
Mardanpour P, Nayernia K, Khodayari S, Khodayari H, Molcanyi M, Hescheler J (2019) Application of stem cell technologies to regenerate injured myocardium and improve cardiac function. Cell Physiol Biochem 53:101–120PubMed
118.
Khodayari S, Khodayari H, Amiri AZ, Eslami M, Farhud D, Hescheler J, Nayernia K (2019) Inflammatory microenvironment of acute myocardial infarction prevents regeneration of heart with stem cells therapy. Cell Physiol Biochem 53:887–909PubMed
119.
Nayernia K, Nolte J, Michelmann HW et al (2006) In vitro-differentiated embryonic stem cells give rise to male gametes that can generate offspring mice. Dev Cell 11:125–132PubMed
120.
Guan K, Nayernia K, Maier LS et al (2006) Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 440:1199–1203PubMed
121.
Mitalipov S, Wolf D (2009) Totipotency, pluripotency and nuclear reprogramming. Engineering of stem cells. Springer, Berlin, pp 185–199
122.
De Paepe C, Krivega M, Cauffman G, Geens M, Van de Velde H (2014) Totipotency and lineage segregation in the human embryo. Mol Hum Reprod 20:599–618PubMed
123.
Ishiuchi T, Torres-Padilla M-E (2013) Towards an understanding of the regulatory mechanisms of totipotency. Curr Opin Genet Dev 23:512–518PubMed
124.
Zhou L-q, Dean J (2015) Reprogramming the genome to totipotency in mouse embryos. Trends Cell Biol 25:82–91PubMed
125.
Falco G, Lee S-L, Stanghellini I, Bassey UC, Hamatani T, Ko MS (2007) Zscan4: a novel gene expressed exclusively in late 2-cell embryos and embryonic stem cells. Dev Biol 307:539–550PubMedPubMedCentral
126.
De Iaco A, Planet E, Coluccio A, Verp S, Duc J, Trono D (2017) DUX-family transcription factors regulate zygotic genome activation in placental mammals. Nat Genet 49:941–945PubMedPubMedCentral
127.
Hendrickson PG, Doráis JA, Grow EJ et al (2017) Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons. Nat Genet 49:925–934PubMedPubMedCentral
128.
Fadloun A, Le Gras S, Jost B, Ziegler-Birling C, Takahashi H, Gorab E, Carninci P, Torres-Padilla M-E (2013) Chromatin signatures and retrotransposon profiling in mouse embryos reveal regulation of LINE-1 by RNA. Nat Struct Mol Biol 20:332PubMed
129.
Hu Z, Tan DEK, Chia G et al (2020) Maternal factor NELFA drives a 2C-like state in mouse embryonic stem cells. Nat Cell Biol 22:175–186PubMed
130.
King NM, Perrin J (2014) Ethical issues in stem cell research and therapy. St Cell Res Ther 5:1–6
131.
Yilmaz A, Benvenisty N (2019) Defining human pluripotency. Cell St Cell 25:9–22
132.
Boroviak T, Loos R, Bertone P, Smith A, Nichols J (2014) The ability of inner-cell-mass cells to self-renew as embryonic stem cells is acquired following epiblast specification. Nat Cell Biol 16:513–525
133.
Sugimura R, Jha DK, Han A et al (2017) Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature 545:432–438PubMedPubMedCentral
134.
Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, Kaufman DS (2009) Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113:6094–6101PubMedPubMedCentral
135.
Schmidt R, Plath K (2012) The roles of the reprogramming factors Oct4, Sox2 and Klf4 in resetting the somatic cell epigenome during induced pluripotent stem cell generation. Genome Biol 13:1–11
136.
Fiedorowicz K, Rozwadowska N, Zimna A et al (2020) Tissue-specific promoter-based reporter system for monitoring cell differentiation from iPSCs to cardiomyocytes. Sci Rep 10:1–13
137.
Wang Y, Mah N, Prigione A, Wolfrum K, Andrade-Navarro MA, Adjaye J (2010) A transcriptional roadmap to the induction of pluripotency in somatic cells. St Cell Rev Rep 6:282–296
138.
Castro-Viñuelas R, Sanjurjo-Rodríguez C, Piñeiro-Ramil M et al (2020) Generation and characterization of human induced pluripotent stem cells (iPSCs) from hand osteoarthritis patient-derived fibroblasts. Sci Rep 10:1–13
139.
Kim Y, Rim YA, Yi H, Park N, Park S-H, Ju JH (2016) The generation of human induced pluripotent stem cells from blood cells: an efficient protocol using serial plating of reprogrammed cells by centrifugation. St Cells Int 2016:1–9
140.
Seki T, Yuasa S, Oda M et al (2010) Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell St Cell 7:11–14
141.
Zhou T, Benda C, Dunzinger S et al (2012) Generation of human induced pluripotent stem cells from urine samples. Nat Protoc 7:2080PubMed
142.
Zapata-Linares N, Rodriguez S, Mazo M, Abizanda G, Andreu EJ, Barajas M, Prosper F, Rodriguez-Madoz JR (2016) Generation and characterization of human iPSC line generated from mesenchymal stem cells derived from adipose tissue. St Cell Res 16:20–23
143.
Wu KH, Wang SY, Xiao QR, Yang Y, Huang NP, Mo XM, Sun J (2019) Small-molecule–based generation of functional cardiomyocytes from human umbilical cord–derived induced pluripotent stem cells. J Cell Biochem 120:1318–1327
144.
Yulin X, Lizhen L, Lifei Z, Shan F, Ru L, Kaimin H, Huang H (2012) Efficient generation of induced pluripotent stem cells from human bone marrow mesenchymal stem cells. Folia Biol 58:221
145.
Teng YD (2019) Functional multipotency of stem cells: biological traits gleaned from neural progeny studies. Seminars in cell & developmental biology. Elsevier, pp 74–83
146.
Wu Y, Zeng J, Roscoe BP et al (2019) Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 25:776–783PubMedPubMedCentral
147.
Zou Y, Zhao Y, Xiao Z, Chen B, Ma D, Shen H, Gu R, Dai J (2020) Comparison of regenerative effects of transplanting three-dimensional longitudinal scaffold loaded-human mesenchymal stem cells and human neural stem cells on spinal cord completely transected rats. ACS Biomater Sci Eng 6:1671–1680PubMed
148.
Khodayari S, Khodayari H, Alizadeh AM (2016) A glance into the future cardiac stem cells. Tehran Univ Med J TUMS Publ 74:223–235
149.
Goodarzi A, Khanmohammadi M, Ai A et al (2020) Simultaneous impact of atorvastatin and mesenchymal stem cells for glioblastoma multiform suppression in rat glioblastoma multiform model. Mol Biol Rep 47:7783–7795PubMedPubMedCentral
150.
Yvernogeau L, Gautier R, Petit L et al (2019) In vivo generation of haematopoietic stem/progenitor cells from bone marrow-derived haemogenic endothelium. Nat Cell Biol 21:1334–1345PubMed
151.
Kao I-T, Yao C-L, Kong Z-L, Wu M-L, Chuang T-L, Hwang S-M (2007) Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD34+ cells. St Cells Dev 16:1043–1052
152.
153.
Blanchet M-R, Bennett JL, Gold MJ, Levantini E, Tenen DG, Girard M, Cormier Y, McNagny KM (2011) CD34 is required for dendritic cell trafficking and pathology in murine hypersensitivity pneumonitis. Am J Respir Crit Care Med 184:687–698PubMedPubMedCentral
154.
Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, Lee DA, Kaufman DS (2013) Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. St Cells Transl Med 2:274–283
155.
Tabatabaei-Zavareh N, Vlasova A, Greenwood CP, Takei F (2007) Characterization of developmental pathway of natural killer cells from embryonic stem cells in vitro. PLoS ONE 2:e232PubMedPubMedCentral
156.
Miller JS, Alley KA, McGlave P (1994) Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+ 7+ NK progenitor. Blood 83(9):2594–2601PubMed
157.
Woll PS, Martin CH, Miller JS, Kaufman DS (2005) Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol 175:5095–5103PubMed
158.
Ni Z, Knorr DA, Clouser CL, Hexum MK, Southern P, Mansky LM, Park I-H, Kaufman DS (2011) Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms. J Virol 85:43–50PubMed
159.
Bonanno G, Mariotti A, Procoli A, Corallo M, Scambia G, Pierelli L, Rutella S (2009) Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage-cells into pseudomature lytic NK cells. BMC Immunol 10:1–15
160.
McCullar V, Oostendorp R, Panoskaltsis-Mortari A, Yun G, Lutz CT, Wagner JE, Miller JS (2008) Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol 36:598–608PubMedPubMedCentral
161.
Frias AM, Porada CD, Crapnell KB, Cabral JM, Zanjani ED, Almeida-Porada G (2008) Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion. Exp Hematol 36:61–68PubMedPubMedCentral
162.
Luevano M, Madrigal A, Saudemont A (2012) Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol 9:310–320PubMedPubMedCentral
163.
Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Verneris MR (2006) Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108:3824–3833PubMedPubMedCentral
164.
Perez SA, Mahaira LG, Sotiropoulou PA et al (2006) Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 18:49–58PubMed
165.
Ning H, Lei H-E, Xu Y-D, Guan R-L, Venstrom JM, Lin G, Lue TF, Xin Z, Lin C-S (2014) Conversion of adipose-derived stem cells into natural killer-like cells with anti-tumor activities in nude mice. PLoS ONE 9:e106246PubMedPubMedCentral
166.
Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, De Witte T, Schaap N, Dolstra H (2011) Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE 6:e20740PubMedPubMedCentral
167.
Davis ZB, Felices M, Verneris MR, Miller JS (2015) Natural killer cell adoptive transfer therapy: exploiting the first line of defense against cancer. Cancer J Sudbury Mass 21:486
168.
Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057PubMed
169.
Lehmann D, Spanholtz J, Osl M, Tordoir M, Lipnik K, Bilban M, Schlechta B, Dolstra H, Hofer E (2012) Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells. St Cells Dev 21:2926–2938
170.
171.
Wang W, Jiang J, Wu C (2020) CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett 472:175–180PubMed
172.
Siegler EL, Zhu Y, Wang P, Yang L (2018) Off-the-shelf CAR-NK cells for cancer immunotherapy. Cell St Cell 23:160–161
173.
Li Y, Hermanson DL, Moriarity BS, Kaufman DS (2018) Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell St Cell 23:181–192
174.
Veluchamy JP, Kok N, van der Vliet HJ, Verheul HM, de Gruijl TD, Spanholtz J (2017) The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments. Front Immunol 8:631PubMedPubMedCentral
175.
Torikai H, Mi T, Gragert L et al (2016) Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Sci Rep 6:1–11
176.
Carlsten M, Childs RW (2015) Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol 6:266PubMedPubMedCentral
177.
Kooreman NG, Kim Y, de Almeida PE et al (2018) Autologous iPSC-based vaccines elicit anti-tumor responses in vivo. Cell St Cell 22:501–513
178.
Mrózek E, Anderson P, Caligiuri MA (1996) Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 87(7):2632–2640PubMed
Metadata
Title
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
Authors
Hamid Khodayari
Saeed Khodayari
Elmira Ebrahimi
Farimah Hadjilooei
Miko Vesovic
Habibollah Mahmoodzadeh
Tomo Saric
Wilfried Stücker
Stefaan Van Gool
Jürgen Hescheler
Karim Nayernia
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 12/2021
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-021-02975-8

Other articles of this Issue 12/2021

Cancer Immunology, Immunotherapy 12/2021 Go to the issue

Original Article

Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas

Clinical Trial Report

Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial

Original Article

Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome

Original Article

Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1.1+ cell activation in mice

Original Article

Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients

Original Article

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits